Ozempic Dosage Chart & Schedule (2026 Guide)
Complete Guide & Evidence (2026)
Official Ozempic dosage titration chart. See the 0.25mg, 0.5mg, 1mg, and 2mg schedule. Track your pens and injection days.
Standard Protocol
Why Track This Protocol
How Fast Do Real Users Move Up the Dose Ladder?
Faster than official titration schedules suggest. Among 269 Shotlee users logging GLP-1 doses in milligrams, 77% — about 3 in 4 — moved up from their starting dose at some point in their logged history, and the median time to that first increase was just 21 days, roughly a week ahead of the 4-week step-up cadence on semaglutide and tirzepatide labels. Some of that reflects compounded or research protocols with faster schedules, and some reflects prescribers starting patients above the lowest rung. Whatever your schedule, log every dose change: appetite, side effects, and weight response often shift noticeably at each step, and that record is what lets you and your prescriber judge whether an increase actually helped. (Aggregated, anonymized Shotlee data as of July 2026.)
Guide FAQs
Official Ozempic dosage titration chart. See the 0.25mg, 0.5mg, 1mg, and 2mg schedule. Track your pens and injection days.
Yes. Shotlee supports tracking Ozempic Dosage Chart doses, side effects, and health metrics. It is free.
Track Your Ozempic Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
📚References & sources
Latest on Ozempic Dosage Chart

Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Anandita Sundar's 7-Year Weight Loss Journey and Body Shaming
Anandita Sundar opens up about her seven-year weight loss journey, highlighting the profound impact of body shaming on mental health and her commitment to prioritizing well-being over societal expectations.
7 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read